NCT00576680View on ClinicalTrials.gov

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

March 29, 2019

Study Completion Date

March 29, 2019

Conditions
Pancreatic Neuroendocrine Tumor
Interventions
DRUG

RAD001

Given orally once a day

DRUG

Temozolomide

Taken orally once a day for one week followed by a one-week break period

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (2)

Novartis
Schering-Plough
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Novartis

INDUSTRY

collaborator

Schering-Plough

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER